Casodex - Nolvadex Combination
Study identifier:7054IL/0044
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Randomised, double-blind, placebo controlled, parallel-group, multicentre Phase II study to assess dose response relationship of Nolvadex (oral tablet) in prophylactic treatment of gynaecomastia and breast pain associated with CASODEX 150 mg (oral tablet), and to assess the tumour control…..
Medical condition
Gynaecomastia
Phase
Phase 2
Healthy volunteers
No
Study drug
Casodex, Tamoxifen
Sex
Male
Actual Enrollment
-
Study type
Interventional
Age
N/A
Date
Study Start Date: 01 Nov 2002
Primary Completion Date: 01 Jun 2005
Study Completion Date: 01 Aug 2005
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: Casodex 150mg once daily |
| Active Comparator: 2 | - |
Contacts
Investigators
Principal Investigator
Yves Fradet
Quebec City
